Mass treatment to eliminate tuberculosis from an island population

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 8, 2014, Pages 899-904

  Hill, Philip C ^a   Dye, C ^b   Viney, K ^c   Tabutoa, K ^d   Kienene, T ^d   Bissell, K ^e,f   Williams, B G ^g   Zachariah, R ^h   Marais, B J ⁱ   Harries, A D ^e,f,j  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c SECRETARIAT OF THE PACIFIC COMMUNITY   (New Caledonia)

^d Ministry of Health and Medical Services   (Kiribati)

^e INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g STELLENBOSCH UNIVERSITY   (South Africa)

^h MÉDECINS SANS FRONTIÈRES   (Belgium)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

Mass treatment; tuberculosis; elimination

Indexed keywords

TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; DISEASE COURSE; DISEASE ELIMINATION; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; FEMALE; HUMAN; INCIDENCE; INFECTION PREVENTION; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MASS TREATMENT; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PACIFIC ISLANDS; POSTPRIMARY TUBERCULOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; AGED; CHILD; FEDERATED STATES OF MICRONESIA; INFANT; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PRESCHOOL CHILD; RECURRENT DISEASE; THEORETICAL MODEL; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; INFANT; LATENT TUBERCULOSIS; MALE; MICRONESIA; MIDDLE AGED; MODELS, THEORETICAL; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; TIME FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 84904579332     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0007     Document Type: Article

References (17)

1. World Health Organization. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis. Geneva, Switzerland: WHO, Stop TB Partnership, 2010.
2. Dye C, Williams B G. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 2008; 5: 653-662. (Pubitemid 351589747)
3. Dye C, Maher D, Weil D, Espinal M, Raviglione M. Targets for global tuberculosis control. Int J Tuberc Lung Dis 2006; 10: 460-462.
4. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Ann Rev Pub Health 2013; 34: 271-286.
5. Comstock G W, Ferebee S H, Hammes L M. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95: 935-943.
6. Comstock G W, Woolpert S F. Preventive treatment of untreated, nonactive tuberculosis in an Eskimo population. Arch Environ Health 1972; 25: 333-337.
7. Comstock G W, Baum C, Snider D E, Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis 1979; 119: 827-830.
8. Horwitz O, Wilbek E, Erickson P A. Epidemiological basis of tuberculosis eradication. 10. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull World Health Organ 1969; 41: 95-113.
9. Daulako E C. Population screening and mass chemoprophylaxis in Kiribati. Int J Lepr Other Mycobact Dis 1999; 67 (Suppl): S23-S25.
10. Sterling T R, Villarino ME, Borisov A S, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166.
11. Gelband H. Regimens of less than six months for treating tuberculosis. Cochrane Database Syst Rev 2000; (2): CD001362.
12. Grosset J H, Singer T G, Bishai W R. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis 2012; 16: 1005-1014.
13. Schlossberg D, Pritchett N, Nnumolu C. Asymptomatic hepatotoxicity in patients treated for tuberculosis and latent tuberculosis. Infect Dis Clin Pract 2007; 15: 320-323. (Pubitemid 47415196)
14. Saukkonen J J, Cohn D L, Jasmer R M, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952. (Pubitemid 44564795)
15. Dossing M, Wilcke J T, Askgaard D S, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tubercle Lung Dis 1996; 77: 335-340. (Pubitemid 26258538)
16. Nuffield Council on Bioethics. Public health: ethical issues. London, UK: Nuffield Council on Bioethics, 2007. http://www.nuffieldbioethics.org/public- health. Accessed May 2014.
17. Bakker M I, Hatta M, Kwenang A, et al. Prevention of leprosy using rifampicin as chemoprophylaxis. Am J Trop Med Hyg 2005; 72: 443-448. (Pubitemid 41278855)